For anterior uveitis, topical steroidal and nonsteroidal anti-inflammatory drops were prescribed frequently along with a cycloplegic agent. In the following days, however, the child complained of chronic floaters with progressively deteriorated visual acuities from 20/25 to 20/200 bilaterally, and posterior segment evaluation revealed vitreitis, retinitis, perivasculitis, and cystoid macular edema (CME). Upon obtaining these findings, a combination of systemic immunosuppressants including corticosteroids (1 mg/kg/d), azathioprine (Imuran , 1-2.5 mg/kg/d), and cyclosporine-A (Sandimmune ; 5 mg/kg/d) were initiated, but she did not respond to this combined therapy after 3 months, and the visual acuities did not increase with refractory bilateral macular edema (Fig. 2a, 3a). Because of the severity of the disease, infliximab (Remicade ; a biologic agent targeting tumor necrosis factor-alpha [TNF-alpha]) was started (5 mg/kg) at weeks 0, 2, 6, and 10, then at each 6-week interval following latent tuberculosis being ruled out by purified protein derivate and chest radiography. The child demonstrated a dramatic and rapid response to repeated infliximab infusions, and both visual acuities increased to 20/20 within 10 days. All other immunosuppressants were gradually discontinued in due course. Anterior chamber evaluation revealed no active inflammation (no cells and no flare), and both retinal vasculitis and macular edema resolved (Fig. 2b, 3b). After 1 year, the first attempt at tapering was made. However, flares during infliximab tapering were encountered even when smaller interval changes, i.e., from 6 to 7 weeks, were attempted initially. Therefore, we had to continue this regimen for years (8 infusions per year) as we experienced uveitis recurrences when we targeted to increase the infusion intervals repeatedly from 6 to 9 weeks. Subsequent tapering attempts were made at every 6-month interval, though the result was the same. After 17 years, we were able to increase the interval finally to 9 weeks, and her ocular symptoms and signs were under control for the recent 3 more years. Further attempts at weaning have been made over the last 1 year, but today, the patient is still having 6 infusions per year. The patient was not co-treated with a DMARD. CBC, liver function tests, blood urea nitrogen, and serum creatinine levels were evaluated every 3 months, and the girl did not show any severe side effects during this period that required the discontinuation of the regimen. Colchicine was added to infliximab by a dermatologist for her recurrent genital ulcers during the last 12 months. Overall, 20 years have passed since the first initiation and nonstop use of infliximab, and the patient is now 34 years old with stabilized vision at 20/20 bilaterally. Due to such a successful clinical response, the patient continues the same regimen with intravenous infliximab infusions (5-mg/kg) that are repeated at each 9-week interval at present.